Safety and Efficacy of Empagliflozin in Hemodialysis - Trial NCT05786443
Access comprehensive clinical trial information for NCT05786443 through Pure Global AI's free database. This Phase 2 trial is sponsored by NYU Langone Health and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NYU Langone Health
Timeline & Enrollment
Phase 2
Jun 01, 2023
Dec 30, 2025
Primary Outcome
Change in Extracellular Volume from Baseline to 12 Weeks,Change in Intracellular Volume from Baseline to 12 Weeks,Change in Total Body Water from Baseline to 12 Weeks,Change in 24-Hour Urine Volume from Baseline to 12 Weeks
Summary
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to
 assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo
 among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05786443
Non-Device Trial